A Phase II Study on Trabectedin in Combination With PPARg Agonist Pioglitazone in Patients With Round Cell Myxoid Liposarcomas or Dedifferentiated G1 and G2 Liposarcomas With Stable Disease After a Monotherapy With Trabectedin (TRABEPIO)
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Pioglitazone (Primary) ; Trabectedin (Primary)
- Indications Liposarcoma; Myxoid liposarcoma
- Focus Therapeutic Use
- Acronyms TRABEPIO
Most Recent Events
- 12 Mar 2024 Planned End Date changed from 2 Feb 2024 to 2 Feb 2025.
- 12 Mar 2024 Planned primary completion date changed from 2 Feb 2024 to 2 Dec 2024.
- 24 Oct 2023 Planned End Date changed from 24 Apr 2023 to 2 Feb 2024.